other material
confidence high
sentiment negative
materiality 0.85
Supernus SPN-820 Phase 2b misses primary endpoint in treatment-resistant depression
SUPERNUS PHARMACEUTICALS, INC.
- SPN-820 showed MADRS score change of -12.3 vs placebo -11.9 at Week 4; p=not significant.
- No statistically significant improvement on any secondary endpoints versus placebo.
- Safety profile consistent with prior trials; few adverse events and well-tolerated.
- CEO Jack Khattar expressed disappointment; will review data with partner Navitor Pharmaceuticals.
- Study enrolled ~250 adults with TRD across 40 U.S. clinical sites.